Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.

Conclusions: Ranibizumab and aflibercept presented similar anatomical and functional outcomes in 18-month follow-up in patients with DME. It is important to determine factors, affecting VA, so as to provide individualized treatment. PMID: 32722955 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32722955?dopt=Abstract

Source: Cutaneous and Ocular Toxicology - July 28, 2020 Category: Toxicology Authors: Chatzirallis A, Theodossiadis P, Droutsas K, Koutsandrea C, Ladas I, Moschos MM Tags: Cutan Ocul Toxicol Source Type: research